Exact Sciences announces public offering of common stock

Special to The Freeman

April 3, 2014

MADISON – Exact Sciences Corp. is planning to sell $125 million worth of shares to the public, according to a statement released by the Madison-based company.

Exact Sciences, which is developing a DNA-based, noninvasive colon cancer test, will use the proceeds from the stock offering to fund its efforts to obtain FDA approval of Cologuard – its colon cancer test. According to the company, it will also use the money to fund Cologuard commercialization activities, product development efforts, and for general corporate purposes.

“The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering,” according to the statement.

Acting as joint book-running managers for the proposed offering are Jefferies LLC; Goldman, Sachs & Co.; and Robert W. Baird & Co.

www.exactsciences.com